Sagard Healthcare Partners provides $40m loan to Valeo Pharma

The proceeds of the loan will fund the acquisition of Canadian rights to three growing commercial stage drugs.

3 August 2022•1 min read

[data-article-body-skeleton]{display:none!important}

JavaScript is required to read this article. Please enable it in your browser and reload the page.